SCHEMBL6709632

SCHEMBL6709632

CC(Nc1ccc(N2CCN(C(=O)c3ccc(Cl)s3)CC2)cc1)(c1cccnc1)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
SMN1; SMN2 Q16637 5/20 0.42
HTT P42858 4/20 0.42
ALDH1A1 P00352 4/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.39
LMNA P02545 1/20 0.39
NAMPT P43490 1/20 0.38
CYP17A1 P05093 1/20 0.38
CYP21A2 P08686 1/20 0.38
CYP11B1 P15538 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
TP53 P04637 1/20 0.37
GFER P55789 1/20 0.37
ADORA2B P29275 1/20 0.37
GAA P10253 1/20 0.37
NPY2R P49146 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715237 0.74 MAPT (0.56) MAPTSMN1; SMN2HTTALDH1A1POLB
SCHEMBL6709641 0.73 MAPT (0.48) MAPTSMN1; SMN2HTTALDH1A1HPGD
SCHEMBL6711133 0.71 MAPT (0.55) MAPTSMN1; SMN2HTTALDH1A1POLB
SCHEMBL6709643 0.69 MAPT (0.48) MAPTSMN1; SMN2HTTALDH1A1HPGD
SCHEMBL6711139 0.69 MAPT (0.59) MAPTSMN1; SMN2HTTALDH1A1POLB
SCHEMBL6709685 0.66 MAPT (0.75) MAPTSMN1; SMN2HTTALDH1A1HPGD
SCHEMBL6709607 0.65 MAPT (0.54) MAPTSMN1; SMN2HTTALDH1A1HPGD
SCHEMBL6715174 0.64 MAPT (0.54) MAPTSMN1; SMN2HTTALDH1A1HPGD
SCHEMBL17707591 0.64 HDAC6 (0.63) MAPTHTTALDH1A1LMNANAMPT
SCHEMBL6709683 0.64 MAPT (0.71) MAPTSMN1; SMN2HTTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same PIERRE FABRE MEDICAMENT (FR) 2004-05-13 US disclosed
EP-1324999-A1 NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME PIERRE FABRE MEDICAMENT (FR) 2003-07-09 EP disclosed
WO-2002030927-A1 NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME PIERRE FABRE MEDICAMENT (FR) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same CBR3, CBR1, HCCS MAPT 4753/4885SMN1; SMN2 4744/4885HTT 4421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.